Introduction
Ischemic stroke is a major cause of worldwide mortality and disability in the growing population of patients over the age of 60. 1 Most ischemic strokes are caused by an occlusion of the cerebral artery either by an embolus or a local thrombus. At present, tissue-type plasminogen activator (tPA) is the only globally approved thrombolytic agent for the treatment of acute ischemic stroke leading to an absolute increase in disability-free survival of 10% for patients treated within 3 h. However, due to its narrow therapeutic time window (3-4.5 h) and the risk of promoting intracerebral haemorrhage (6.7%), tPA is given to a very limited number of patients. Moreover, only a third of treated patients have a good outcome, and increased risk of early death from intracranial haemorrhage (2%) has been reported. 2 tPA has also shown neurotoxicity in experimental models of cerebral ischemia. 3, 4 Therefore, a combination treatment that would reduce the deleterious effects of tPA, while maintaining or improving its efficacy, might extend its clinical indication. Even though recent randomized controlled trials with stent retrievers have proved the efficacy of endovascular stroke therapy with and without tPA, 5 the limited access to some thrombi and the ischemic injury require greater insights into thrombolysis improvement and neuroprotection. Matrix metalloproteinases (MMPs) comprise a family of at least 25 zinc-dependent endopeptidases that digest extracellular matrix (ECM) and play a pivotal role in the physiopathology of the mammalian central nervous system. In the first phases after ischemia, a deregulated expression of MMPs has been described to increase acute neurovascular disruption and cerebral injury. In particular, MMP-mediated alterations lead to blood-brain barrier (BBB) leakage, cerebral edoema, haemorrhage, leucocyte infiltration and progressive inflammatory reactions underlying brain tissue loss. 6 In animal models, MMPs have been shown to display critical activities throughout the repair phases of cerebral ischemia, particularly during angiogenesis and reestablishment of cerebral blood flow, providing detrimental and/or beneficial effects in the course of the poststroke injury and repair phases depending on the studied MMP. 7 Under such background, we established that MMP10 has a profibrinolytic effect in ischemic stroke model, reducing infarct size via thrombin activatable fibrinolysis inhibitor (TAFI)-dependent mechanisms. 8 Furthermore,
MMP10 is notably increased in neurons of the human ischemic brain, while MMP9 is highly expressed in brain microvessels, 9 indicating a selective cell-dependent MMP secretion and opening up the possibility of selectively targeting specific MMPs. Considering the unmet need for new therapies for ischemic brain treatment, we assessed the potential of MMP10 alone and in combination with tPA, as a novel thrombolytic strategy in ischemic stroke. By using a thromboembolic stroke model we examined the effect of both treatments on infarct size, 10 and their efficacy in terms of neuroprotection.
Methods

Animal procedures and experimental thromboembolic stroke
Mice (C57BL/6J, male 4-months-old, Harlan, Envigo, Barcelona, Spain) were randomized and anaesthetized with 2.5% isoflurane. Rectal temperature was maintained at 37 ± 0.5 C throughout the surgical procedure using a feedback-regulated heating system. A catheter was inserted into the tail vein to allow intravenous (i.v.) administration of 200 mL saline, tPA (10 mg/kg) and active rhMMP10 (6.5 mg/kg, $2 nM) alone or in combination with tPA, 20 min after clot formation. MMP10 dose was chosen according to previous studies. 8 Stroke was induced by thrombin injection into the middle cerebral artery (MCA) as previously described. 10 The entire procedure was monitored by laser Doppler, and analysis was performed blinded to the treatment protocol (n = 10-17/ group). Time to reperfusion was defined as the time to partial (50%) reperfusion. Experiments were performed in accordance with European Communities Council Directives (2010/63/EU) guidelines for the care and use of laboratory animals and were approved by the University of Navarra Animal Research Review Committee.
Behavioural experiments
Behavioural assessments were done in a subgroup of n = 5 mice/treatment. For all behavioural testing, observers were blinded to the treatment.
Locomotor activity
Horizontal locomotor activity was measured for 5 min in an open field, which consisted of a square arena (35 Â 35 cm 2 , 30 cm height) made of white nylon, using a video tracking system (Ethovision XT11.5, Noldus Information Technology B.V., The Netherlands), in a softly illuminated room. Total path length (cm) was analysed.
Pole task
To evaluate co-ordination, mice were placed head-upward at the top of a vertical gauze-wrapped circular wooden pole (diameter = 1 cm; height = 55 cm) with video monitoring from the side. Prior to surgery, testing mice were trained for three trials to ensure each mouse was able to perform the task with ease before stroke. Each testing session lasted for a maximum of 180 s.
Expression and purification of GFP tagged recombinant human MMP10
Human proMMP10-EmGFP fusion protein was generated using GeneArt Gene Synthesis service (Thermo Fisher, Madrid, Spain). Briefly, synthetic whole human MMP10 ORF was assembled, inserted into vector backbone pENTR221, subcloned into pcDNA6.2_C-EmGFP-DEST_A321, and verified by sequencing. HEK293 (Human Embryonic Kidney fibroblasts, Lonza, Barcelona, Spain) cells were transfected with Lipofectamine (Thermo Fisher Scientific) and grown before clonal selection in the presence of blasticidin (Thermo Fisher Scientific). Supernatants were screened for the production of proMMP10-EmGFP by fluorimetry (ex 489/em 509 nm), MMP10 ELISA (R&D Systems, Abindong, UK) and western blot with an anti-MMP10 antibody (MAB9101, R&D Systems). Cells were grown in Hyperflasks (Corning, Madrid, Spain), switched to serum free DMEM (Gibco, Madrid, Spain) and supernatants were collected every 48 h, concentrated (VivaFlow 200; 30 kDa cut off, Sartorious, Madrid, Spain) and stored at -20 C until purification. A two-step purification strategy was designed, comprising hydrophobic interaction with HyTrap Butyl Fast Flow column (GE Healthcare, Madrid, Spain) after ammonium sulphate precipitation, followed by immunoaffinity chromatography with a HiTrap NHS-activated HP column (GE Healthcare) coupled with an anti-MMP10 antibody. Sample purity was assessed by sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) followed by staining with Gelcode Blue Stain Reagent (Thermo Fisher Scientific).
Histological analysis after brain ischemia
Mice were euthanized by CO 2 inhalation 24 h post-ischemia, perfused with paraformaldehyde 4% and brains frozen in isopentane. Brain sections were immunostained for MMP10 (rabbit anti-MMP10, Acris, Herford, Germany and goat anti-MMP10, Heidelberg, Germany), GFP (rabbit anti-GFP, Abcam, Cambridge, UK) and cell markers for neurons (monoclonal anti-NeuN, Millipore, Madrid, Spain), activated microglia (rabbit anti-Iba1, Wako, Neuss, Germany), astrocytes (rabbit GFAP, Dako, Glostrup, Denmark) and endothelial cells (rat CD31, Dianova, Hamburg, Germany) followed by incubation with Alexa fluor-labelled secondary IgGs (Thermo Fisher Scientific), and were visualized under confocal laser scan microscope (Ziess, Madrid, Spain LSM-510 Meta). Assessment of the infarct volume was carried out on cryostat-cut coronal brain sections (20 mm) stained with thionine. One section out of every 10 was stained and analysed (covering the entire lesion). An image analysis system (Image J, National Institutes of Health) was used to measure the lesion corresponding to the non-stained area.
Effect of tPA and MMP10 on plasmin and MMPs activity
In order to assess whether tPA is a potential substrate for MMP10, both proteins were incubated (1/5, enzyme/substrate ratio) at 37 C for 24 h in assay buffer (100 mM NaCl, 5 mM CaCl 2 , 20 mM Tris-HCl, pH = 8). Digestion products were analysed by SDS-PAGE and stained with GelCode Blue Stain Reagent (Pierce, Madrid, Spain).
To determine activity changes in the presence of MMP10, tPAinduced plasminogen activation and tPA amydolytic activity were performed using the synthetic substrate S-2251 (Chromogenix, Barcelona, Spain) and Chromozyme tPA (Roche Diagnostics, Mannheim, Germany), respectively.
Concomitantly, MMP10 activity (2 nM) was assayed with a fluorogenic peptide for stromelysins (ES002, Fluorogenic Peptide Substrate II, R&D Systems) and analysed with a spectrophotofluorometer (Envision, Perkin Elmer, Madrid, Spain).
Human brain endothelial cell viability and permeability
We used a human brain endothelial cell line (hCMEC/D3) as a model of BBB, to perform in vitro experiments. 11, 12 Cell viability was measured 
Transendothelial electrical resistance (TEER)
1 Â 10 5 hCMEC/D3 cells were seeded on top of a rat collagenI-coated polycarbonate porous cell culture insert/membranes with a pore size of 0.4 mm (Corning). hCMEC/D3 cells were grown for 2 days in EGM-2 medium and switched to OGD conditions to treat them with tPA (100 mg/mL), active MMP10 (2 nM) or the combination for 6 h. Electrical resistance was measured using an EVOM resistance meter (World Precision Instruments, Hertfordshire, England).
Obtention of cell lysates for western blot analysis
To analyse the expression of tight junction (TJ) proteins (occludin and claudin-5), hCMEC/D3 cells were treated with tPA (100 mg/mL), MMP10 (2 nM), or the combination for 6 h in hypoxia (0.5% O 2 ). ERK1/2 or Akt pathways activation (5 mg), was analysed by western blot after incubation for 1 h in hypoxia.
Endothelial permeability
To determine whether MMP10 was able to cross the BBB in vitro, hCMEC/D3 cells were seeded in rat collagenI-coated Costar Transwell filters (pore-size 0.4 lm, Corning), stimulated with MMP10 (2 nM) or tPA/MMP10 and maintained in OGD for 6 h. Supernatants were taken from the upper and lower part of Boyden chambers and analysed by ELISA (MMP10, R&D Systems) or western blot.
Western blots
Samples from cell lysates, supernatants or protein mixtures were separated by SDS-PAGE (4-12% Bis-Tris gel, Invitrogen, Madrid, Spain), iBLOT transferred (Invitrogen) and developed by a chemiluminescent substrate (TMA-6, Lumigen, Southfield, Mi, USA). Blots were incubated overnight with primary antibodies (monoclonal anti-human MMP10, R&D Systems; rabbit anti-occludin, BD Systems, Madrid, Spain; rabbit anti-claudin-5, Invitrogen; rabbit anti-pERK1/2, Cell signaling Technology, Leiden, The Netherlands; monoclonal anti-pAkt, Cell Signaling Technology; sheep antitPA, INRA and anti-GluN1, Santa Cruz and Jerulem, Israel) followed by 1 h incubation with required peroxidase-conjugated secondary antibodies. For the loading controls, membranes were stripped (20 min, 37 C, Thermo Scientific) and incubated overnight at 4 C with the nonphosphorylated forms of ERK or Akt (Cell Signaling Technology) and b-actin (SigmaçAldrich, Madrid, Spain), followed by incubation with a HRP-conjugated antibodies and developed as explained above.
Gene expression analysis
hCMEC/D3 cells were seeded on 48 well plates, grown until confluence, stimulated with 2 nM MMP10 in serum free RPMI and harvested at baseline, 2, 6, and 24 h post-stimulation. RNA from cells was extracted (Abi Prism 6100, Applied Biosystems, Madrid, Spain) and 1 lg was reverse transcribed with random primers and Moloney Murine Leukaemia Virus (MMLV) reverse transcriptase (Invitrogen). Real-time PCR was performed on an ABI PRISM V R 7900HT sequence detector (Applied Biosystems) using TaqMan V R gene expression assays (Applied Biosystems) for human Mmp2 (Hs00234422_m1), and Mmp9 (Hs00234579_m1). Gapdh (Hs.PT.39a.22214836, IDT, Leuven, Belgium) was used as housekeeping gene.
Cortical neuron primary cultures
Experiments were performed on pregnant swiss mice (Janvier, France). Anaesthesia was induced using 5% isoflurane (Aerrane, Baxter, Guyancourt, France) in a mixture of O 2 /N 2 O (30%/70%). Deeply anesthetized mice were euthanized by CO 2 inhalation, the embryos (n = 5) were extracted and their brains removed for further processing. 13 Neuronal cultures were prepared from cortex-free meninges and dissected, dissociated (DMEM), and plated on 24-well plates coated with poly-D-lysine (0.1 mg/mL) and laminin (0.02 mg/mL). Cells were cultured in DMEM supplemented with 5% foetal bovine serum, 5% horse serum (both from Invitrogen) and 2 mM glutamine. Cultures were maintained at 37 C in a humidified 5% CO 2 atmosphere. To inhibit glial proliferation, cytosine b-D-arabinoside (10 lM) was added after 3 days in vitro (DIV) to the cortical cultures and cells were used at 12-13 DIV.
Excitotoxic neuronal death
Excitotoxicity was induced by exposure of neurons to N-methyl-Daspartate (NMDA, 12.5 lM) in serum-free DMEM supplemented with 10 lM of glycine for 24 h. NMDA was applied alone or together with tPA (20 lg/mL to 300 nM) and/or MMP10 (2 nM) and/or aMMP10 antibody (10 mg/mL, monoclonal anti-human MMP10, R&D Systems) as in previous experiments.
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MMP10 toxicity (0.5-50 mg/mL) was assayed in the absence of NMDA after 24 h with LDH assay (Roche Diagnostics, Mannheim, Germany). The maximal neuronal death (full kill, FK) was determined in cells exposed to 500 lM NMDA while background was determined in unstimulated cells.
Calcium video-imaging in neurons
Experiments on cortical neurons were performed at room temperature on the stage of a Leica DMI6000B inverted microscope equipped with a 150W Xenon high stability lamp and a Leica 40Â, 1.3 numerical aperture epifluorescence oil immersion objective. Fura-2 (excitation 340 and 380 nm, emission 510 nm) ratio images were acquired with a Digital CMOS camera (Hamamatsu-Massy Cedex, France, ORCA-Flash2.8 C11440-10C) and digitalized (2048 Â 2048) using Metafluor V R 6.1 software (Universal Imaging Corporation). Serum-free cell cultures were loaded with 10 mM fura-2 AM (Invitrogen) for 45 min, washed, and treated with NMDA (2 Â 25 mM for 30 s) before incubating for 45 min with all treatments (tPA 300 nM, MMP10 2 nM and aMMP10 antibody 10 mg/mL), and re-exposed to NMDA (2 Â 25 mM for 30 s).
Statistical analysis
Data are presented as mean ± SEM. Statistical significance was determined using either two-way ANOVA or Kruskal-Wallis followed the BenjaminiHochberg (BH) correction for multiple comparisons. Two-way factorial ANOVA was performed on cell culture data for the comparison of treatments among different experiments. Here we assessed if the results for the treatments changed across the different days. As no significant interaction was observed between treatment and experiment, we assumed that the result for the treatments were consistent for all days, worked with both factors independently and compared the effect of the treatments using the BH correction of P values. Cell culture data are presented as percentage of control group. All analyses were performed with Stata-12 software. A two-tailed value of P < 0.05 was considered significant.
Results
The combination of tPA and MMP10 reduces infarct size in the thromboembolic stroke model
Previous work showed the therapeutic potential of MMP10 administration (6.5 mg/kg, 2 nM) for acute ischemic stroke and the synergistic profibrinolytic effect with tPA in vitro. 8 Here, we wanted to evaluate whether the combination of MMP10 with standard care (tPA) could further improve ischemic stroke outcome. Average reduction in cerebral blood flow was similar in all groups (saline: 87.0 ± 17.3%; tPA: 78.4 ± 12.2%; MMP10: 79.7 ± 8.9; tPA/MMP10: 86.4 ± 12.2%). The percentage of animals with partial reperfusion (> _50%) 1 h after stroke was similar in mice treated with tPA (75%), MMP10 (80%) or tPA/MMP10 (80%), and higher (v 2 , P < 0.05) than control (30%). Likewise, time to arterial recanalization was alike in tPA, MMP10 or tPA/MMP10 treated animals ( Figure 1A ) suggesting a similar thrombolytic activity for all treatments.
Administration of MMP10 alone or in combination with tPA significantly reduced infarct size as compared with saline. Interestingly, the combination tPA/MMP10 reduced volume lesion vs tPA (P < 0.05; Figure  1B ), although no differences were found with MMP10. No cerebral haemorrhages were observed after any treatment (data not shown).
Behavioural studies performed to determine association between lesion volume and functional outcome showed faster moving speed in mice with lower lesion volume at 24 h in open field test (r = -0.46, P = 0.043 for total distance; r = -0.47, P = 0.034 for medium speed, and r = 0.43, P = 0.056 for motionless time). Despite this correlation detected using an open field test, there were no concomitant differences in pole test data after stroke (data not shown).
These data indicate that even if MMP10, alone or in combination with tPA, does not contribute to a further improvement in reperfusion time right after stroke, there must be other MMP10-dependent mechanisms helping to preserve tissue integrity in later stages. In fact, by immunohistochemical analysis, we could detect MMP10 expression in murine brain tissue after stroke, confirming the observations made in human ischemic brains.
9 Figure 1C shows the co-expression of MMP10 with endothelial cells (CD31) and the neuronal marker (NeuN) within the infarcted and peri-infarcted areas but not with activated microglia marker Iba1 or astrocytes (GFAP). MMP10 expression was lower, almost undetected, in the non-ischemic areas of the brain (see Supplementary material online, Figure S1 ).
The combination of tPA with MMP10 does not modify their enzymatic activities
To study whether reduced brain damage observed upon coadministration of tPA/MMP10 could be mediated by proteolytic modification of tPA by MMP10, active rhMMP10 was incubated with recombinant tPA. As shown by Coomassie staining (Figure 2A ), MMP10 did not modify tPA, as the band pattern was similar to that obtained in the presence of GM6001, a broad inhibitor of MMPs. Moreover, as shown in Figure 2B and C, MMP10 did not modify tPA activity, measured by tPA chromogenic substrate or by the amount of generated plasmin, using aprotinin as negative control. We further analysed the functionality of MMP10, and observed no effect of tPA on MMP10 activity ( Figure 2D ), suggesting that the protective effect of tPA/MMP10 combination is not the result of a variation in MMP10 or tPA enzyme activities.
Endothelial cell viability and electrical resistance upon tPA/MMP10 stimulation
Our in vivo observation showing decreased tissue damage in the presence of MMP10, together with its localization in endothelial cells and neurons in response to tissue injury, led us to study the effect of MMP10 on endothelial cells in a well-established in vitro model of BBB integrity. Experiments were performed on immortalized human brain capillary endothelial cells (hCMEC/D3) in normoxia or oxygen-glucose deprivation (OGD) conditions upon tPA, MMP10 or tPA/MMP10 stimulation. We first performed experiments to determine the dose of tPA able to reduce endothelial cell viability in vitro. The dose of 100 mg/mL of tPA significantly reduced cell survival compared with control and 13 mg/mL tPA in both, normoxia (survival % of control: 100 ± 2.5 control; 91 ± 2.0 13 mg/mL tPA; 79 ± 2.9 100 mg/mL tPA; P < 0.05) and OGD conditions (survival % of normoxia control: 66 ± 1.9 control; 65 ± 2.6 13 mg/ mL tPA; 58 ± 2.9 100 mg/mL tPA; P < 0.05), and was therefore chosen to perform further experiments.
In normoxia, MMP10 (2 nM) did not modify cell survival compared with control conditions (Figure 3A) , while it decreased significantly in tPA survival as compared with control, whereas tPA slightly reduced cell viability (P < 0.01), indicating an attenuation of tPA-detrimental effect on the endothelial monolayer.
TEER was measured to assess ionic permeability across the endothelial monolayer under ischemic conditions. Single stimulation of hCMEC/ D3 with MMP10 did not change the endothelial resistance as compared with control, whereas tPA resulted in a $30% reduction (P < 0.05, Figure  3B ). The combination of tPA/MMP10 increased TEER compared with tPA alone (P < 0.05), indicating a better preservation of endothelial integrity to the ion movements in the presence of MMP10.
Endothelial cell permeability after tPA/ MMP10 treatment in vitro and in vivo
Endothelial cell permeability to macromolecules (BSA and MMP10) was measured in OGD. Stimulation of hCMEC/D3 cells with tPA or MMP10 increased FITC-BSA permeability by 50% compared with untreated cells (P < 0.01). As shown in Figure 3C , the combination of tPA/MMP10 did not further increase endothelial permeability.
In addition, we assess whether MMP10 could cross the endothelial barrier and extravasate, when adding it alone or in combination with tPA. Western blot analysis did not show MMP10 in lower chambers in any condition (see Supplementary material online, Figure S2A ). However, using a more sensitive ELISA assay, we observed that MMP10 alone did not pass through the endothelial monolayer, whereas combined with tPA it reached the lower chamber ( Figure 3D ), suggesting that MMP10 could get to brain parenchyma in ischemic conditions when tPA is present. These in vitro results were confirmed in vivo by morphological analysis of tissues. Mice were administered GFP-tagged MMP10 alone, or in combination with tPA, and brain sections were analysed 24 h postischemia to determine by immunofluorescence the presence of GFP, as a readout of MMP10, in brain parenchyma. As shown in Figure 3E , GFP staining at the lesion size was hardly detectable in brains from mice receiving MMP10 alone. In contrast, those injected with the combination showed GFP þ staining mainly in neurons, localized around cell nucleus.
These data indicate that MMP10 treatment only crosses the BBB and reach neurons when co-administered with tPA. To determine whether MMP10 had an effect on the endothelial monolayer through the regulation of other MMP family members, experiments were done in vitro by stimulating hCMEC/D3 with MMP10 to measure Mmp2 and Mmp9 genes. MMP10 reduced significantly Mmp2 mRNA expression profile at 24 h (see Supplementary material online, Figure S2B ), while MMP9 levels were undetectable in all explored time points (not shown).
MMP10 modulates claudin-5 levels in endothelial cells
The differential effect of MMP10 alone or in combination with tPA on BBB permeability, and electrical resistance led us to study TJ proteins. We analysed the expression of claudin-5, associated exclusively with small molecule passage 14 and occludin, mainly involved in flow of macromolecules. 15 Western blot analysis in lysates of hCMEC/D3 cells, maintaining the same stimulation conditions, showed a marked reduction of claudin-5 ($70%) in tPA treated cells (P < 0.05, Figure 4A ), while it remained similar to control in MMP10 or tPA/MMP10 stimulated cells. Occludin expression was reduced after tPA, MMP10 or tPA/MMP10 stimulation ( Figure 4B ), suggesting a selective effect of MMP10 on claudin-5 expression. Next, we evaluated the potential involvement of MAPK signalling implicated in the TJ's composition. As shown in Supplementary material online, Figure S3 , MMP10 alone or in combination with tPA decreased the phosphorylation of ERK1/2 but not of Akt (data not shown), indicating that OGD-induced ERK pathway can be inactivated by MMP10.
MMP10 reverses tPA-induced excitotoxicity in cortical neurons
The ability of MMP10 to cross the BBB and reach the brain parenchyma prompted us to study the effect of MMP10 and tPA/MMP10 in neurons. We first analysed neuronal sensitivity and found that MMP10 had no effect on neuron survival at the dose used for the in vivo experiments (2 nM), but dose-dependently reduced cell survival from 5 nM on ( Figure 5A) . We observed that tPA/NMDA condition enhanced neuronal death, as compared with NMDA alone (P < 0.01). This effect was prevented when MMP10 was co-administered with tPA (NMDA/tPA/MMP10). Besides, addition of an antibody against MMP10 (aMMP10) completely abolished MMP10 neuroprotective effect (NMDA/tPA/MMP10/aMMP10) ( Figure 5B) .
We then used calcium video-imaging assays to test tPA-driven boosting of NMDA receptor (NMDAR) signalling, in the presence or absence of MMP10. Figure 5C and D shows the percentage of responsiveness after treatment for each cortical neuron analysed. As evidenced in Figure 5C , NMDA exposure led to reproducible waves of calcium influx that were boosted by 26.5% in the presence of tPA (300 nM; n = 108 cells). MMP10 alone did not affect calcium influx (2.0%; n = 100), but prevented tPAinduced boosting of NMDAR signalling (0.6%; vs tPA alone; n = 100) and this effect was blocked by an aMMP10 antibody (24.5%; n = 109). Figure 5D represents the percentage of stimulation or inhibition calculated for each individual cell showing that the combination of tPA and MMP10 inhibited the tPA detrimental effect on calcium influx (P < 0.01), which was reversed in the presence of antibody against MMP10 activity (P < 0.01). A differential function for single chain (sc)-tPA and two chain (tc)-tPA on NMDARmediated calcium influx and neurotoxicity has been demonstrated. 16 Therefore, we determined tPA conversion from sc to tc molecule in presence of MMP10, although no difference in the tc-sc ratio could be observed (see Supplementary material online, Figure S4 ). Moreover, we examined the possibility that cleavage of the N-Terminal GluN1 subunit by MMP10 could be responsible of the NMDAR signalling blockade, as previously observed for MMP7. 17 Nevertheless, GluN1 subunit of NMDAR was not affected after MMP10 treatment (see Supplementary material online, Figure S5 ).
Discussion
Our present data confirm that the single administration of MMP10 is as efficient as tPA to reduce infarct size, and reports for the first time that the addition of MMP10 to tPA achieves further reduction in brain damage after experimental thromboembolic ischemic stroke. This effect was not due to increased MMP10 or tPA-induced plasmin activity, suggesting that additional mechanisms operate to reduce lesion size in our model. In fact, the fewer side effects of MMP10 on ECs and neurons, preventing tPA-induced decrease in TEER and expression of claudin-5, and blocking tPA-induced neuronal excitotoxicity, suggest that MMP10 alone or combined with tPA could be a useful and novel treatment in ischemic stroke. (n = 12/condition, three independent cultures) and (n = 6 for control and full-kill conditions). (B) NMDA-enhanced excitotoxicity (12.5 mM) after tPA (20 mg/mL) treatment was reduced when MMP10 (2 nM) was co-administered. A aMMP10 neutralizing antibody (10 mg/mL) impaired the beneficial effect of MMP10. (n = 3 independent experiments, n = 2-3/condition; *P < 0.01 and **P < 0.001 compared between groups, # P < 0.05 and ## P < 0.01 compared with NMDA condition, ns: not significant). Statistical significance was assessed using the factorial two-way ANOVA followed by BH correction for multiple comparisons. After normalizing data to median of full kill values. (C) Calcium video-imaging was performed on primary cultures of cortical neurons (12 DIV). After two successive control NMDA stimulations, neurons were incubated for 45 min with either buffer (control, n = 109 cells), tPA alone (300 nM, n = 108 cells) or in the presence of MMP10 (2 nM, n = 100 cells), or a blocking antibody (aMMP10, 10 mg/mL, n = 109 cells). Each dot represents one cell. (D) Left panel, percentage of NMDA responsiveness on each condition after/before NMDA stimulations. Right panel, percentage of stimulation or inhibition after incubation was calculated for each individual cell and reported as percentage of responsiveness for each group (mean ± SEM; n = 3 independent experiments; n.s. not significant; * P < 0.01, #<0.05). NMDA, N-methyl-Daspartate.
Over the past few years, mounting evidence has shown that MMPs participate in the pathophysiology of cerebral ischemia either directly, through degradation of brain matrix substrates or indirectly, through activation of other bioactive molecules. 18 We had previously demonstrated that MMP10 enhances tPA-induced fibrinolysis in vitro, and that its single administration reduces reperfusion time after thromboembolic stroke, probably acting in conjunction with endogenous tPA. 8 In this study, we report that MMP10 and tPA/MMP10 combination have similar efficacy to tPA, in terms of shortening reperfusion time with no evidence of intracranial haemorrhage in any experimental group. 8, 10 Given the high thrombolytic efficiency of tPA, it could be possible that combination of MMP10 and tPA may not improve the maximal fibrinolysis achieved by tPA right after stroke. The smaller infarct size observed in MMP10 and tPA/MMP10 groups, as compared with saline, and the further reduction with tPA/MMP10 as compared with tPA, led us to postulate that, besides its profibrinolytic effect, MMP10 may trigger mechanisms involved in preserving tissue integrity and could mitigate tPA negative side-effects. tPA increases the inflammatory response that activates MMP9, promoting ECM degradation, increased permeability and extended brain tissue damage. 19, 20 Furthermore, in animal models of cerebral ischemia, MMP expression is increased significantly and related to BBB disruption, edoema formation or haemorrhagic transformation. 21, 22 However, studies in mouse models of ischemic stroke postulate different functions for MMPs, even opposite, in response to brain damage. For instance, BBB leakage was reduced in MMP9 but not in MMP2 knock-out mice, 23, 24 moreover MMP2 seems to be expressed early after brain injury related to better outcome 25 while circulating MMP3 levels decrease, 26 and studies on MMP13 gave rise to contradictory results. 27, 28 Furthermore, other studies have reported that endogenous MMP responses may be key mediators in stroke recovery, being required for microvascular recanalization or neuronal stem cell proliferation and migration. 29, 30 To address whether the administration of MMP10 and tPA/MMP10 could affect BBB integrity and neuronal excitotoxicity, we used a wellcharacterized human cell line (hCMEC/D3), which had been reported to represent an in vitro human BBB model for transport studies 11, 12 and neuron cultures. As already described, 31 tPA reduced endothelial viability under ischemic conditions in marked contrast with MMP10, which even prevented the detrimental effect of tPA. Interestingly, MMP10 maintained electrical resistance when co-administered with tPA under ischemic conditions, but was unable to avoid tPA-induced permeability to macromolecules, as evidenced by MMP10 crossing through EC barrier in vitro and in vivo. Increased neuronal signal of GFP-MMP10 in mice treated with the combination compared with MMP10, suggests that it can reach neurons and exert a neuroprotective effect. Though MMPs typically act extracellularly, data from several groups have reported that these enzymes may also act within the cell to target selected proteins. 32, 33 This size-selective preservation of the BBB integrity by MMP10 might be in part associated with the differential modulation of claudin-5 and occludin. Claudin-5, a major cell adhesion molecule of TJs in brain ECs, 34, 35 was preserved in MMP10 and tPA/MMP10 treated cells as compared with tPA, whereas occludin rendered a similar reduction with all treatments. In vivo, claudin-5 deficiency has been associated with severe defects on small molecule BBB passage 14 while occludin has been mainly related to the regulation of macromolecule flux (e.g. BSA or MMP10). Therefore, we propose that MMP10 could have a protective effect by preserving and even preventing tPA-promoted decrease in claudin-5, which concomitantly would preserve endothelial electrical resistance. We performed additional experiments to assess the involvement of the MAPK and PI3Ks/Akt pathways, which have been implicated in TJ composition and BBB permeability. 36 ERK activation in OGD injury has been associated with apoptosis, cytokine stimulation and endothelial cell death. 37 Moreover, several reports have demonstrated that the inhibition of ERK1/2 pathway reduces ischemic infarct volume. 38 In the current study, we found that MMP10 alone or in combination with tPA reduces ERK1/2 phosphorylation in hCMEC/D3 cultures, suggesting a possible mechanism for the protective effects of MMP10 on endothelial barrier properties.
Interestingly, our results demonstrate that tPA-induced cellular excitoxicity, 3 by enhancement of NMDAR-mediated calcium influx, was prevented by MMP10. We and others have demonstrated that strategies blocking tPA-mediated excitotoxicity improve stroke outcome. Moreover, reduced infarct size and better neurological outcome have been reported in tPA knockout mice after ischemic stroke. 3, 39 Considering this evidence, it is indeed tempting to speculate that the beneficial effect of MMP-10 could be mediated by a blockade of tPAmediated excitotoxicity. Reports of MMPs on neuronal toxicity are scarce, but previous data suggested that MMP9 is associated with excitotoxicity and neuronal damage, 40 while recent evidence points that MMP7 can cleave the GluN1 subunit of NMDAR, preventing calcium influx and neuronal death. 17 Our results showing that GluN1 was not affected by MMP10 suggest that its cleavage is not the mechanism responsible for the NMDAR signalling blockade.
Limitations of the study
Differences in blood flow during reperfusion time cannot be ruled out and a more precise measurement of blood flow during ischemia/reperfusion would be required. Additional studies will be necessary to identify the mechanisms triggered by MMP10 to reduce tPA-induced excitotoxicity and the biological meaning of the MMP10 inside the neurons. In summary, this study shows that MMP10 alone or in combination reduces brain infarct size by preserving neurovascular unit and protecting it even from the detrimental effects of tPA. Further studies are required to determine the safety profile of this new strategy to be translated to ischemic stroke patients.
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